Capricor Therapeutics has completed its US marketing application for deramiocel, a cell therapy the US biotech hopes will ...

In a statement, Neumora revealed that the KOASTAL-1 study missed its primary endpoint, with navacaprant failing to achieve a ...

The start-up – founded by investment group Flagship Pioneering – said that OPL-0401 did not meet either the primary or ...

This tiered approach allows investors to engage at the level they’re most comfortable with, sparking their interest with a ...

Regeneron has bought Oxular, a UK-based specialist in retinal diseases, in a move that bolsters its already strong position ...

In a deal valued at up to $1 billion, Roche has licensed rights to a DLL3-directed antibody-drug conjugate (ADC) from China's ...

The team from the University of Bath in the UK, Poland's Kozminski Academy and Lund University in Sweden have concluded that ...

The JV was set up in 2001 and has become increasingly peripheral to Hutchmed's core business of developing novel therapies ...

The UK's Poolbeg Pharma has disclosed that it is in talks over a possible combination with Hookipa, an Austrian biotech that ...

Now, Novartis hopes to be able to share the data with regulatory authorities in 2025, including the US FDA, in the hope of ...

But with cancer remaining as one of the most prevalent and deadly forms of disease worldwide, there are a staggering number ...

Daiichi Sankyo has claimed approval in Japan, its home market, for TROP2-targeting antibody-drug conjugate (ADC) datopotamab ...